03.10.22
IntraBio Ltd. is pleased to share that the Phase III pivotal trial with N-acetyl-L-leucine (IB1001-301) clinical trial has enrolled over 30% of the target number of patients in the first month of recruitment. The study, which investigates N-acetyl-L-leucine (IB1001) for the treatment of Niemann-Pick disease Type C (NPC), will enroll a total of approximately 52 patients across all international sites. Since recruitment commenced in September 2022, sixteen (20) patients have been screened...
Read more08.09.22
19.08.22
19.08.22
28.06.22